Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 203 entries
Sorted by: Best Match Show Resources per page
Should we celebrate outstanding achievement in general practice training?.

The British journal of general practice : the journal of the Royal College of General Practitioners

Kiely B, Sheth S, Dhar S, Balendra A, McGlone A.
PMID: 25452521
Br J Gen Pract. 2014 Dec;64(629):616-7. doi: 10.3399/bjgp14X682717.

No abstract available.

Cite
Kiely B, Sheth S, Dhar S, et al. Should we celebrate outstanding achievement in general practice training?. Br J Gen Pract. 2014;64(629):616-7doi: 10.3399/bjgp14X682717.
Kiely, B., Sheth, S., Dhar, S., Balendra, A., & McGlone, A. (2014). Should we celebrate outstanding achievement in general practice training?. The British journal of general practice : the journal of the Royal College of General Practitioners, 64(629), 616-7. https://doi.org/10.3399/bjgp14X682717
Kiely, Bridget, et al. "Should we celebrate outstanding achievement in general practice training?." The British journal of general practice : the journal of the Royal College of General Practitioners vol. 64,629 (2014): 616-7. doi: https://doi.org/10.3399/bjgp14X682717
Kiely B, Sheth S, Dhar S, Balendra A, McGlone A. Should we celebrate outstanding achievement in general practice training?. Br J Gen Pract. 2014 Dec;64(629):616-7. doi: 10.3399/bjgp14X682717. PMID: 25452521; PMCID: PMC4240126.
Copy Download .nbib Format: NLM
The Importance of Sample Size for Reproducibility of tDCS Effects.

Frontiers in human neuroscience

Minarik T, Berger B, Althaus L, Bader V, Biebl B, Brotzeller F, Fusban T, Hegemann J, Jesteadt L, Kalweit L, Leitner M, Linke F, Nabielska N, Reiter T, Schmitt D, Spraetz A, Sauseng P.
PMID: 27679568
Front Hum Neurosci. 2016 Sep 13;10:453. doi: 10.3389/fnhum.2016.00453. eCollection 2016.

No abstract available.

Cite
Minarik T, Berger B, Althaus L, et al. The Importance of Sample Size for Reproducibility of tDCS Effects. Front Hum Neurosci. 2016;10:453doi: 10.3389/fnhum.2016.00453.
Minarik, T., Berger, B., Althaus, L., Bader, V., Biebl, B., Brotzeller, F., Fusban, T., Hegemann, J., Jesteadt, L., Kalweit, L., Leitner, M., Linke, F., Nabielska, N., Reiter, T., Schmitt, D., Spraetz, A., & Sauseng, P. (2016). The Importance of Sample Size for Reproducibility of tDCS Effects. Frontiers in human neuroscience, 10453. https://doi.org/10.3389/fnhum.2016.00453
Minarik, Tamas, et al. "The Importance of Sample Size for Reproducibility of tDCS Effects." Frontiers in human neuroscience vol. 10 (2016): 453. doi: https://doi.org/10.3389/fnhum.2016.00453
Minarik T, Berger B, Althaus L, Bader V, Biebl B, Brotzeller F, Fusban T, Hegemann J, Jesteadt L, Kalweit L, Leitner M, Linke F, Nabielska N, Reiter T, Schmitt D, Spraetz A, Sauseng P. The Importance of Sample Size for Reproducibility of tDCS Effects. Front Hum Neurosci. 2016 Sep 13;10:453. doi: 10.3389/fnhum.2016.00453. eCollection 2016. PMID: 27679568; PMCID: PMC5020062.
Copy Download .nbib Format: NLM
Research in Reproduction: Challenges, Needs, and Opportunities.

Frontiers in physiology

Ivell R.
PMID: 28228729
Front Physiol. 2017 Feb 08;8:46. doi: 10.3389/fphys.2017.00046. eCollection 2017.

No abstract available.

Cite
Ivell R. Research in Reproduction: Challenges, Needs, and Opportunities. Front Physiol. 2017;8:46doi: 10.3389/fphys.2017.00046.
Ivell, R. (2017). Research in Reproduction: Challenges, Needs, and Opportunities. Frontiers in physiology, 846. https://doi.org/10.3389/fphys.2017.00046
Ivell, Richard. "Research in Reproduction: Challenges, Needs, and Opportunities." Frontiers in physiology vol. 8 (2017): 46. doi: https://doi.org/10.3389/fphys.2017.00046
Ivell R. Research in Reproduction: Challenges, Needs, and Opportunities. Front Physiol. 2017 Feb 08;8:46. doi: 10.3389/fphys.2017.00046. eCollection 2017. PMID: 28228729; PMCID: PMC5297420.
Copy Download .nbib Format: NLM
2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Epilepsy currents

Dlugos D, Worrell G, Davis K, Stacey W, Szaflarski J, Kanner A, Sunderam S, Rogawski M, Jackson-Ayotunde P, Loddenkemper T, Diehl B, Fureman B, Dingledine R.
PMID: 27330452
Epilepsy Curr. 2016 May-Jun;16(3):192-7. doi: 10.5698/1535-7511-16.3.192.

No abstract available.

Cite
Dlugos D, Worrell G, Davis K, et al. 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Curr. 2016;16(3):192-7doi: 10.5698/1535-7511-16.3.192.
Dlugos, D., Worrell, G., Davis, K., Stacey, W., Szaflarski, J., Kanner, A., Sunderam, S., Rogawski, M., Jackson-Ayotunde, P., Loddenkemper, T., Diehl, B., Fureman, B., Dingledine, R. (2016). 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy currents, 16(3), 192-7. https://doi.org/10.5698/1535-7511-16.3.192
Dlugos, Dennis, et al. "2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects." Epilepsy currents vol. 16,3 (2016): 192-7. doi: https://doi.org/10.5698/1535-7511-16.3.192
Dlugos D, Worrell G, Davis K, Stacey W, Szaflarski J, Kanner A, Sunderam S, Rogawski M, Jackson-Ayotunde P, Loddenkemper T, Diehl B, Fureman B, Dingledine R. 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Curr. 2016 May-Jun;16(3):192-7. doi: 10.5698/1535-7511-16.3.192. PMID: 27330452; PMCID: PMC4913858.
Copy Download .nbib Format: NLM
A-V canal and related congenital heart defects.

The Heart bulletin

KIELY B, ADAMS P, ANDERSON RC, LESTER RG.
PMID: 14408980
Heart Bull. 1960 May-Jun;9:51-4.

No abstract available.

Cite
KIELY B, ADAMS P, ANDERSON RC, et al. A-V canal and related congenital heart defects. Heart Bull. 1960;9:51-4
KIELY, B., ADAMS, P., ANDERSON, R. C., & LESTER, R. G. (1960). A-V canal and related congenital heart defects. The Heart bulletin, 951-4.
KIELY, B, et al. "A-V canal and related congenital heart defects." The Heart bulletin vol. 9 (1960): 51-4.
KIELY B, ADAMS P, ANDERSON RC, LESTER RG. A-V canal and related congenital heart defects. Heart Bull. 1960 May-Jun;9:51-4. PMID: 14408980.
Copy Download .nbib Format: NLM
[Foreign aid for the development of medical teaching in the University of Chile].

Revista medica de Chile

VIEL B.
PMID: 13925846
Rev Med Chil. 1961 Aug;89:571-5.

No abstract available.

Cite
VIEL B. [Foreign aid for the development of medical teaching in the University of Chile]. Rev Med Chil. 1961;89:571-5
VIEL, B. (1961). [Foreign aid for the development of medical teaching in the University of Chile]. Revista medica de Chile, 89571-5.
VIEL, B. "[Foreign aid for the development of medical teaching in the University of Chile]." Revista medica de Chile vol. 89 (1961): 571-5.
VIEL B. [Foreign aid for the development of medical teaching in the University of Chile]. Rev Med Chil. 1961 Aug;89:571-5. Spanish. PMID: 13925846.
Copy Download .nbib Format: NLM
Mobilization and utilization of cyanogenic glycosides: the linustatin pathway.

Plant physiology

Selmar D, Lieberei R, Biehl B.
PMID: 16665975
Plant Physiol. 1988 Mar;86(3):711-6. doi: 10.1104/pp.86.3.711.

In the seeds of Hevea brasiliensis, the cyanogenic monoglucoside linamarin (2-beta-d-glucopyranosyloxy-2-methylpropionitrile) is accumulated in the endosperm. After onset of germination, the cyanogenic diglucoside linustatin (2-[6-beta-d-glucosyl-beta-d-glucopyranosyloxy]-2- methylpropionitrile) is formed and exuded from the endosperm of Hevea seedlings. At the same...

Cite
Selmar D, Lieberei R, Biehl B. Mobilization and utilization of cyanogenic glycosides: the linustatin pathway. Plant Physiol. 1988;86(3):711-6doi: 10.1104/pp.86.3.711.
Selmar, D., Lieberei, R., & Biehl, B. (1988). Mobilization and utilization of cyanogenic glycosides: the linustatin pathway. Plant physiology, 86(3), 711-6. https://doi.org/10.1104/pp.86.3.711
Selmar, D, et al. "Mobilization and utilization of cyanogenic glycosides: the linustatin pathway." Plant physiology vol. 86,3 (1988): 711-6. doi: https://doi.org/10.1104/pp.86.3.711
Selmar D, Lieberei R, Biehl B. Mobilization and utilization of cyanogenic glycosides: the linustatin pathway. Plant Physiol. 1988 Mar;86(3):711-6. doi: 10.1104/pp.86.3.711. PMID: 16665975; PMCID: PMC1054557.
Copy Download .nbib Format: NLM
Analysis of tryptophan, tyrosine and related dipeptides in mouse brain by isocratic high-performance liquid chromatography with switchable wavelength fluorescence detection.

Journal of pharmaceutical and biomedical analysis

Viell B, Weidler B, Krause B, Vestweber KH.
PMID: 16867364
J Pharm Biomed Anal. 1988;6(6):933-8. doi: 10.1016/0731-7085(88)80112-2.

Tryptophan (Trp) and tyrosine (Tyr) are pharmacologically active compounds which, after administration of adequate doses, are increased in level in the brain, and stimulate neurotransmitter synthesis. Trp and Tyr containing dipeptides were tested as possible substitutes with regard to...

Cite
Viell B, Weidler B, Krause B, et al. Analysis of tryptophan, tyrosine and related dipeptides in mouse brain by isocratic high-performance liquid chromatography with switchable wavelength fluorescence detection. J Pharm Biomed Anal. 1988;6(6):933-8doi: 10.1016/0731-7085(88)80112-2.
Viell, B., Weidler, B., Krause, B., & Vestweber, K. H. (1988). Analysis of tryptophan, tyrosine and related dipeptides in mouse brain by isocratic high-performance liquid chromatography with switchable wavelength fluorescence detection. Journal of pharmaceutical and biomedical analysis, 6(6), 933-8. https://doi.org/10.1016/0731-7085(88)80112-2
Viell, B, et al. "Analysis of tryptophan, tyrosine and related dipeptides in mouse brain by isocratic high-performance liquid chromatography with switchable wavelength fluorescence detection." Journal of pharmaceutical and biomedical analysis vol. 6,6 (1988): 933-8. doi: https://doi.org/10.1016/0731-7085(88)80112-2
Viell B, Weidler B, Krause B, Vestweber KH. Analysis of tryptophan, tyrosine and related dipeptides in mouse brain by isocratic high-performance liquid chromatography with switchable wavelength fluorescence detection. J Pharm Biomed Anal. 1988;6(6):933-8. doi: 10.1016/0731-7085(88)80112-2. PMID: 16867364.
Copy Download .nbib Format: NLM
The molecular biology of vasopressin and oxytocin genes.

Journal of neuroendocrinology

Ivell R, Burbach JP.
PMID: 19215526
J Neuroendocrinol. 1991 Dec 01;3(6):583-5. doi: 10.1111/j.1365-2826.1991.tb00321.x.

No abstract available.

Cite
Ivell R, Burbach JP. The molecular biology of vasopressin and oxytocin genes. J Neuroendocrinol. 1991;3(6):583-5doi: 10.1111/j.1365-2826.1991.tb00321.x.
Ivell, R., & Burbach, J. P. (1991). The molecular biology of vasopressin and oxytocin genes. Journal of neuroendocrinology, 3(6), 583-5. https://doi.org/10.1111/j.1365-2826.1991.tb00321.x
Ivell, R, and Burbach, J P. "The molecular biology of vasopressin and oxytocin genes." Journal of neuroendocrinology vol. 3,6 (1991): 583-5. doi: https://doi.org/10.1111/j.1365-2826.1991.tb00321.x
Ivell R, Burbach JP. The molecular biology of vasopressin and oxytocin genes. J Neuroendocrinol. 1991 Dec 01;3(6):583-5. doi: 10.1111/j.1365-2826.1991.tb00321.x. PMID: 19215526.
Copy Download .nbib Format: NLM
Vasopressinergic innervation of the bovine pineal gland: is there a local source for arginine vasopressin?.

Molecular and cellular neurosciences

Olcese J, Sinemus C, Ivell R.
PMID: 19912907
Mol Cell Neurosci. 1993 Feb;4(1):47-54. doi: 10.1006/mcne.1993.1006.

Although the presence of arginine vasopressin (AVP) in the mammalian pineal has been characterized biochemically, the source of this nonapeptide hormone remains enigmatic. Most earlier data pointed to an extrapineal origin, although some recent evidence suggests intrapineal synthesis of...

Cite
Olcese J, Sinemus C, Ivell R. Vasopressinergic innervation of the bovine pineal gland: is there a local source for arginine vasopressin?. Mol Cell Neurosci. 1993;4(1):47-54doi: 10.1006/mcne.1993.1006.
Olcese, J., Sinemus, C., & Ivell, R. (1993). Vasopressinergic innervation of the bovine pineal gland: is there a local source for arginine vasopressin?. Molecular and cellular neurosciences, 4(1), 47-54. https://doi.org/10.1006/mcne.1993.1006
Olcese, J, et al. "Vasopressinergic innervation of the bovine pineal gland: is there a local source for arginine vasopressin?." Molecular and cellular neurosciences vol. 4,1 (1993): 47-54. doi: https://doi.org/10.1006/mcne.1993.1006
Olcese J, Sinemus C, Ivell R. Vasopressinergic innervation of the bovine pineal gland: is there a local source for arginine vasopressin?. Mol Cell Neurosci. 1993 Feb;4(1):47-54. doi: 10.1006/mcne.1993.1006. PMID: 19912907.
Copy Download .nbib Format: NLM
Folate and neural tube defects.

Asia Pacific journal of clinical nutrition

Field B.
PMID: 24398182
Asia Pac J Clin Nutr. 1993 Nov;2:43-5.

The multifactorial aetiology of neural tube defects has stimulated many theories related to dietary factors in pregnancy. The results of the Medical Research Council Study confirm that folate has a protective effect if taken in the 3 months prior...

Cite
Field B. Folate and neural tube defects. Asia Pac J Clin Nutr. 1993;2:43-5
Field, B. (1993). Folate and neural tube defects. Asia Pacific journal of clinical nutrition, 243-5.
Field, B. "Folate and neural tube defects." Asia Pacific journal of clinical nutrition vol. 2 (1993): 43-5.
Field B. Folate and neural tube defects. Asia Pac J Clin Nutr. 1993 Nov;2:43-5. PMID: 24398182.
Copy Download .nbib Format: NLM
Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

MedChemComm

Prevatt-Smith KM, Lovell KM, Simpson DS, Day VW, Douglas JT, Bosch P, Dersch CM, Rothman RB, Kivell B, Prisinzano TE.
PMID: 22442751
Medchemcomm. 2011 Dec;2(12):1217-1222. doi: 10.1039/C1MD00192B.

Previous structure-activity relationship studies of salvinorin A have shown that modification of the acetate functionality off the C-2 position to a methoxy methyl or methoxy ethyl ether moiety leads to increased potency at KOP receptors. However, the reason for...

Cite
Prevatt-Smith KM, Lovell KM, Simpson DS, et al. Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. Medchemcomm. 2011;2(12):1217-1222doi: 10.1039/C1MD00192B.
Prevatt-Smith, K. M., Lovell, K. M., Simpson, D. S., Day, V. W., Douglas, J. T., Bosch, P., Dersch, C. M., Rothman, R. B., Kivell, B., & Prisinzano, T. E. (2011). Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. MedChemComm, 2(12), 1217-1222. https://doi.org/10.1039/C1MD00192B
Prevatt-Smith, Katherine M, et al. "Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A." MedChemComm vol. 2,12 (2011): 1217-1222. doi: https://doi.org/10.1039/C1MD00192B
Prevatt-Smith KM, Lovell KM, Simpson DS, Day VW, Douglas JT, Bosch P, Dersch CM, Rothman RB, Kivell B, Prisinzano TE. Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. Medchemcomm. 2011 Dec;2(12):1217-1222. doi: 10.1039/C1MD00192B. PMID: 22442751; PMCID: PMC3307802.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 203 entries